Dermatoporosis, an emerging disease. Case report

Domínguez, María Lorena Re; Ortíz, Beatriz Di Martino; Masi, Mirtha Rodríguez; Domínguez, Oilda Knopfelmacher; Lezcano, Lourdes Bolla Argüello de

doi:10.7241/ourd.20162.52

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antiseptics are commonly defined as substances that kill (bactericidal) or inhibit (bacteriostatic) the growth of bacteria [35]. The antimicrobial preservative chlorocresol (CLC, 4-chloro-3-methylphenol), the detergent cetylpyridinium chloride (CPC, 1-hexadecylpyridinium chloride) which can reduce gingivitis and was previously able to prevent dental plaque [36,37] and polyaminopropyl biguanide (PBI), also known as polyhexamethylene biguanide, that has been shown to be effective against Staphylococcus aureus amongst others and is used as disinfectant in swimming pools [38,39], were tested here because they have known antimicrobial properties and are already commercially used. Therefore obtaining approval for a new application would be simplified.…”

Section: Risk Factors For Bacterial Vaginosis Includementioning

confidence: 99%

Rennin and lecithin to treat vaginosis in a lesbian and bisex woman

Martini¹

2022

Our Dermatol Online

View full text Add to dashboard Cite

Vaginosis seems to be more severe, fastidious and afflictive in lesbians, since they are accustomed to employ sexual toys and use to douche more frequently that women who lead a life more correct and regular (even having multiple sex encounters during the week). Many are the OTC remedies, especially acid syndets and detergents, or many infusions made with particular herbs (Aloe barbadensis, coconut milk, garlic decoction, tea tree oil, mauve or rhodiola extracts), even if they yield to relaps too often. Many Researchers have proposed the usage of amphoteric tensides for this scope of treating vaginosis, even there is no hitherto reliable sources in the international literature. The AA have made up their mind to create a cosmetic cocktail containg a biological protease that acts as an amphoteric surfactant (presenting the two hydrophilic and lypophilic moyeties) and the soy lecithin. Results appear to be interesting and satisfying.

show abstract

Section: Risk Factors For Bacterial Vaginosis Includementioning

confidence: 99%

Rennin and lecithin to treat vaginosis in a lesbian and bisex woman

Martini¹

2022

Our Dermatol Online

View full text Add to dashboard Cite

show abstract

“…El daño solar, el tratamiento con corticoides tópicos o sistémicos y el tratamiento anticoagulante son factores exacerbantes de la insuficiencia cutánea crónica. Las primeras manifestaciones clínicas aparecen a la edad de 60 años, pero los signos de enfermedad completamente desarrollados son evidentes en las personas de entre 70 y 90 años; afecta a 1 de cada 3 personas (2). La prevalencia de la dermatoporosis no está muy definida hoy en día.…”

Section: Introductionunclassified

Seguridad y grado de aceptación de un calcetín protector cutáneo en pacientes con dermatoporosis y/o cambios cutáneos por insuficiencia venosa crónica

Marín¹,

Montero²,

Vázquez³

et al. 2020

Rev. enferm. vasc.

View full text Add to dashboard Cite

El objetivo de este estudio fue analizar la seguridad y tolerancia de un calcetín protector cutáneo confeccionado con tecnología Regenactiv® en pacientes con dermatoporosis y/o cambios cutáneos por insuficiencia venosa crónica.Se realizó un estudio prospectivo en la consulta de heridas del Centro de Especialidades Periféricas Vicente Soldevilla entre noviembre y diciembre de 2018. Se incluyeron todos los pacientes que acudieron a la consulta de heridas que presentaban dermatoporosis en la piel de la pierna y/o alteraciones dérmicas por insuficiencia venosa crónica.El 89% (n=18) de los pacientes no presentaron eventos adversos, un único paciente (5%) presentó un evento adverso en forma de erosión. Otro paciente (5%) no pudo emplear el calcetín porque no se adaptaba al perímetro de su pierna.Un 48% (n=10) de los pacientes puntuaron la comodidad del calcetín con un 9 o 10, un 38% (n=8) entre un 7 y un 8, y sólo un 5% con un 6 sobre 10 en la escala Likert. El paciente que no pudo utilizar el calcetín de manera continuada, no valoró este ítem. El 90% (n=18) de los pacientes no manifestaron dolor durante el tiempo de utilización del calcetín. Un 10% (n=2) de los pacientes alcanzaron un nivel de dolor de 3-4 en la escala de EVA.El uso de un calcetín protector confeccionado con tecnología textil Regenactiv® por parte de pacientes con dermatoporosis y/o afectación cutánea secundaria a insuficiencia venosa crónica produce escasos efectos adversos y es bien tolerado. Además, puede ser empleado bajo dispositivos de compresión terapéutica.

show abstract

Update on Dermatoporosis

Vanzi¹,

Toma²

2020

Journal of the Dermatology Nurses' Association

View full text Add to dashboard Cite

Skin fragility caused by structural and functional deterioration is ubiquitous especially in older people, and it determines a significant impact on quality of life. Dermatoporosis is a relatively new term used to describe the chronic skin insufficiency and fragility syndrome marked by morphological and functional manifestations. It is much more than a merely cosmetic problem. Dermatoporosis' manifestations may determine an increased risk of morbidity and mortality. Severe stages of dermatoporosis may determine skin lacerations, deep dissecting hematomas, and skin necrosis. Most patients affected by dermatoporosis are between 70 and 90 years old, but first clinical signs may start at around 40–60 years. Nurses have a key role in preventing dermatoporosis and managing its complications, promoting patients' safety and skin integrity.

show abstract

Dermatoporosis, an emerging disease. Case report

Cited by 4 publications

References 6 publications

Rennin and lecithin to treat vaginosis in a lesbian and bisex woman

Rennin and lecithin to treat vaginosis in a lesbian and bisex woman

Seguridad y grado de aceptación de un calcetín protector cutáneo en pacientes con dermatoporosis y/o cambios cutáneos por insuficiencia venosa crónica

Update on Dermatoporosis

Contact Info

Product

Resources

About